Neurotech International Ltd. · ASX:NTI
Neurotech International — Investor Presentation (July 2018)
34 slides from Neurotech International's investor presentation, Jul 12, 2018
Slide 1: Bridging to a better life – Investor presentation
For personal use only Bridging to a better life Investor presentation Neurotech International Limited (ASX: NTI) | 12 July 2018
Slide 2: Agenda
Agenda For personal use only ✓ Introduction ✓ US Clinical Trial results – discussion by Professor Frederick Carrick ✓ Neurotech update – Wolfgang Storf - Certifications – existing & FDA submission - Improved Mente Autism device set for release - Distribution network - Marketing activities - Achievem
Slide 3: US Clinical Trial results
For personal use only US Clinical Trial results Professor Frederick Carrick – Senior Research Fellow BCMHR in association with University of Cambridge The full results of a US clinical trial using Mente Autism has been published by medical journal Frontiers in Neurology. https://bit.ly/2KyZn0n 3
Slide 4: Cerebral Cortex: Its locations, functions & disorders
Cerebral Cortex: Its locations, functions & disorders For personal use only • Major cortical functions of the integrated sensory-motor system are spatial orientation & self motion perception 4
Slide 5: Cortical functions
Cortical functions For personal use only • Depend on auditory, vestibular, visual & somatosensory input • All four systems (auditory, vestibular, visual & somatosensory) provide us with redundant information about the position & motion of the body relative to the external space 5
Slide 6: CONSORT 2010 Flow Diagram
For personal use only CONSORT 2010 Flow Diagram sor Excluded (n=644) + Not meeting inclusion criteria (n=113) [> « Declined to participate (n=266) + Other reasons (n=265) Randomized (n=83) Allocated to treatment (n=41) Allocated to control (n=42) + Received allocated intervention (n=41) + Received a
Slide 7: Mente Autism study
For personal use only Mente Autism study 7
Slide 8: For personal use only
For personal use only 8
Slide 9: For personal use only
For personal use only 9
Slide 10: For personal use only
For personal use only 10
Slide 11: For personal use only
For personal use only 11
Slide 12: For personal use only
12 nay 3 - 2 =] a Zz : : Fs \ : te bs 2 FE = : 3 ; ®) oO a J .] .J J J ‘J ’ Pre JO1JUOD sAnoy Ajuo esn feuosied 10}
Slide 13: For personal use only
For personal use only 13
Slide 14: For personal use only
For personal use only 14
Slide 15: Active vs Control group qEEG pre and post
Neurotech Active Group (n=12) — Control Group (n=12) Delta Beta High Beta Delta Beta High Beta 1-4HZ 12-25HZ 25-30 HZ 1-4HZ 12-25HZ 25-30 HZ Pre QEEG Pg a & r ® Pre QEEG 3 minus . g Post QEEG i Teest RN (-@) ®, +3 15
Slide 16: Paired T Tests Pre and Post Treatment Delta EEG Activity
For personal use only Paired T Tests Pre and Post Treatment Delta EEG Activity: Statistical Significance in only the ACTIVE Group Frontal Pre and Post ‘Centro Pre and Post Posterior Pre and Post FP1 Pre and Post | : a = ej = . = . P = 0,004 Cohen's d= 1.091 P = 0.040 Cohen's d = 582 P = 0.098 Cohen'
Slide 17: Beta Paired T Tests Pre and Post Treatment EEG Activity
Neurotech Beta Paired T Tests Pre and Post Treatment EEG Activity: Statistical Significance in Both Groups Control P3 Pre and Post Controt T3 Pre and Post Active P4 Pre and Post Active Té Pre and Post = na == | — a P = 0.012 Cohen's d = 386 P = 0.039 Cohen's d = 420 ‘ActiveFP1 Pro and Post Active T4
Slide 18: Paired T Tests Pre and Post BRIEF
Paired T Tests Pre and Post BRIEF: Statistical Significance in Active Group Only After Removal of 5 Subjects with Inconsistency scores = 7 — P = 0.040 Cohen's d = 409 BRIEF Metacognitive P = 0.050 Cohen's d = 478 BRIEF Global EX = P = 0.018 Cohen's d = 524 BRIEF Org Mat SS P = 0,040 Cohen's d = .334
Slide 19: Paired T Tests Pre and Post ASIEP3 & QABF-Escape
Paired T Tests Pre and Post ASIEP3 & QABF-Escape: Statistical Significance in Active Group Only ASIEP3 Active Pre and Post QABF-Escape Active Pre and Post ry | = ry ° P = 0.001 Cohen's d = .781 P = 0.003 Cohen's d = 626 Cohen's d Effect Size Pre 0.2 = small Os=lage” POST 0.8 = Large Neurotech 19
Slide 20: For personal use only
Delta (1-4 Hz) Beta (12-25 Hz) High Beta (25-30 Hz) Variable Group Pre Post Pp values* Pre Post p value Pre Post p value Mean Mean -Partialn’ | Mean Mean —Partialn’ | Mean Mean _ Partial n’ (Std.Error) (Std.Error) Obs.-power) (std.Error) (Std.Error) ObS. power! (Std.Error) (Std.Error) Obs. power 132
Slide 21: For personal use only
For personal use only Neurotech [mmm] | AH | 152) ay ay oe pale | 0604 a ° 0710s oss ons m2 on 23 ne $90 97 or 373 eg | Oe | ate: on UR (77 ene C2 TT o» =o Max Sway ooss ors we 19 m7 m4 $72 8 sa ne nz Game | sere | ary) dia «= 8 | Se | ua cam OF | ey sy | yey prae | 0500 0.680 0221 0951 __ oss 077%
Slide 22: Questionnaire SRS-2
Questionnaire srs-2 ewes Saeetn = Freres = = Neurotech communication Grou Control Active pt Control Active Control Active p* Control Active p*_—Control_ Active pt Control Active Pro Mean(SWiEm 7559 76.12 0.084 7453 7218 0223 7694 76A1 ASOT 7518 TOMI 025181887029 0782 7818 © 76820127 2585 505 (eer es
Slide 23: Overview on EEG data
Overview on EEG data Reductions in delta & beta band with active treatment compared to sham For personal use only • Significant statistical p values in active group qEEG only • In the single case analysis it was shown that the pre & post of active subjects have resulted in normalised values - Substa
Slide 24: Overview on EEG data
Overview on EEG data Reductions in delta & beta band with active treatment compared to sham For personal use only • Paired t-test were performed within the groups • The paired t-test between the Active & Sham showed clearly a significant improvement (towards normalisation) of central & temporal delt
Slide 25: Neurotech update
For personal use only Neurotech update Wolfgang Storf – CEO, Neurotech International 25
Slide 26: Certifications
Certifications The Mente Autism device already has European CE Marking & TGA Registration, thus enabling sales in For personal use only Europe, Middle East & Australia. The Company will seek to also obtain US FDA clearance for the device. Current Certifications & Registrations FDA Submission Process
Slide 27: Improved Mente Autism device set for release
Improved Mente Autism device set for release For personal use only Complete Mente Autism Kit What’s new in the improved Mente? Improvements to: ✓ wi-fi connectivity ✓ synchronisation ✓ usability ✓ firmware ✓ application Comprising headband, power supply, earphones, sensors, Quickguide, cloud system
Slide 28: Distribution network & marketing activities
Distribution network & marketing activities For personal use only ✓ Direct mailing to contacts ✓ Outreach to media & press contacts ✓ Social media activity to target potential customers ✓ Autism group events ✓ Dedicated Mente pages on distributor websites • Marketing & distribution Marketing & distr
Slide 29: Spreading awareness of Mente Autism
Spreading awareness of Mente Autism For personal use only 29
Slide 30: Update: Italian neurofeedback centres
Update: Italian neurofeedback centres For personal use only • Series of commercial & marketing activities organised over in Italy (Orvieto, Umbria & Corato, Bari) led by distribution partner Promosalute • Promosalute have engaged a leading marketing company with the aim of creating a highly targeted
Slide 31: Updated Mente Autism website
Updated Mente Autism website For personal use only ✓ Fresher look with new imagery ✓ Direct ‘calls to action’ ✓ Pre-sales assessment to gauge eligibility to use Mente Autism ✓ Usability improvements www.mentetech.com 31
Slide 32: Key Achievements & Next Milestones
Key Achievements & Next Milestones For personal use only Achievements Looking Forward… Substantial achievements in the last 18 months: Neurotech is focussed on continuing to let science do the talking, and bringing Mente Autism to the parents & children ✓ Mar – Sep 2017: Secured new Austrian, Greece
Slide 33: Q&A session
For personal use only Q&A session 33
Slide 34: Websites
For personal use only www.neurotechinternational.com www.mentetech.com
Neurotech International — Investor Presentation (July 2018) on 6ix